Sun Pharma Ends Development of SCD-044 After Phase 2 Trials Fail to Meet Efficacy Goals

Sun Pharmaceutical Industries has announced the discontinuation of its investigational drug SCD-044 following phase 2 clinical trials that failed to meet their primary endpoints. The trials, which focused on evaluating the drug’s efficacy in treating psoriasis and atopic dermatitis, did not yield the desired results necessary to advance development. Despite this outcome, the company reported no significant safety concerns associated with the drug during the trial period.

The phase 2 studies were conducted to assess both the therapeutic potential and safety profile of SCD-044 in patients with these chronic skin conditions. While the trials confirmed that the drug posed no major risks to patient health, it did not demonstrate sufficient effectiveness in achieving its intended treatment goals. Based on these findings, Sun Pharma has decided to halt further development of SCD-044 and redirect resources toward other projects within its pipeline.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: June 4, 2025

Related posts:

Access to Free COVID-19 Tests in the United States DrugPatentWatch Guide Focuses on Four Strategies for Optimizing Pharmaceutical Pricing DrugPatentWatch: 5 Factors Influence Pharmaceutical Company Valuation AI Drug Repurposing Could Cut Neurological Treatment Development Costs by 70%

Author

Mark Chiang